Organovo

San Diego, United States Founded: 2007 • Age: 19 yrs Listed
Functional three-dimensional human tissues are developed using 3D bioprinting technology.

About Organovo

Organovo is a publicly listed company based in San Diego (United States) founded in 2007. Functional three-dimensional human tissues are developed using 3D bioprinting technology. Organovo has raised $6.67 million across 13 funding rounds from investors including NIH, HHS and National Science Foundation. Organovo offers products and services including 3D Bioprinted Tissues and Bioprinting Technology. Its focus areas include High Tech, 3D Printing, Applications and Healthcare. Its legal entity is Organovo, Inc. Its competitors include Dimension Inx, Prellis Biologics and FluidForm Bio; 2 of its 3 listed competitors have raised funding.

Company details

Organovo has developed ExVive technology to design and create functional, three-dimensional human tissues for medical research and therapeutic applications with its proprietary scaffold-free 3D bioprinting technology. It works on the principle of interaction between drops of liquid, which come together to form multicellular aggregates, similarly mammalian cells form aggregates without the use of any component. The company calls these cellular aggregates as Bio-Ink, which would form intact tissues.It offers services in 3D Human Liver Tissue Testing, Human Liver Tissue Testing performance, and 3D Human Kidney Tissue Testing. It partners with academic institutes focusing on a single therapeutic area to develop disease modeling and therapeutics using 3D Bioprinting. The company has received orphan drug designation from the US FDA for its 3D bioprinted liver therapeutic tissue for alpha-1 antitrypsin deficiency.

Key Metrics
  • Total Equity Funding
    $6.67M (USD)

    in 13 rounds

  • Latest Funding Round
    $1.66M (USD), Grant

    Jul 2017

  • Investors
    NIH

    & 2 more

Products & Services of Organovo

Organovo offers a comprehensive portfolio of products and services, including 3D Bioprinted Tissues and Bioprinting Technology.

3D Bioprinted Tissues
Biotech Products

Human tissues for drug testing and research applications.

Bioprinting Technology
Research Platforms

Tools for creating 3D tissues in biomedical studies.

Apps and channels of Organovo

its YouTube channel Organovo Holdings, Inc. has 1.16K subscribers and 16 videos.

Organovo Holdings, Inc.
YouTube 1.16K subscribers 16 videos Music
Open channel

Videos from Organovo

The most watched videos on Organovo's YouTube channel, Organovo Holdings, Inc. (1.16K subscribers). Click a video to play it here.

The Bioprinting Process
358.4K views
Company Profile: Organovo
82.5K views
2014 - Organovo Stem Cell Meeting on the Mesa
6.6K views
Webinar: 3D Bioprinted Therapeutic Liver Tissue
4.9K views

More on Organovo Holdings, Inc..

Funding Insights of Organovo

Organovo has successfully raised a total of $6.67M across 13 strategic funding rounds. The most recent funding activity was a Grant round of $1.66 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $6.67M
  • Total Rounds 13
  • Last Round Grant β€” $1.66M
  • First Round $5M

    (Jun 2005)

  • Investors Count 3

Latest 10 of 13 funding rounds of Organovo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2017$1.66MGrant––
Apr 2012$290,053Grant––
Mar 2012$15.2MPost-IPO––
–
Mar 2012$290,053Grant––
Nov 2011$3.49MSeries A––
–
Sep 2010$125,114Grant––
Aug 2010$125,114Grant––
Jun 2010$178,250Seed––
–
Sep 2009$142,511Grant––
Aug 2009$142,511Grant––
Valuation history

3 investors in total: 3 institutional.

Investors in Organovo

Organovo has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and National Science Foundation.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Public health and human services are overseen by HHS.
1953hhs.gov
Drug discovery services are provided to the biopharma sector.
1887nih.govUnited States
A government-backed foundation providing seed-stage investments to support small businesses.
1950nsf.govArlington, United States
Premium access

Investor details for Organovo

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Organovo

10 people are tracked at Organovo (1 in leadership, 9 in team).

NameRoleGroup
Cari Rosette
Director Drug DiscoveryLeadership
Curtis Tyree
Svp, Strategy And Business DevelopmentTeam
Eric Benson
Lead EngineerTeam
Haylee Aidnik
Scientist Ii, HistologyTeam
Nicholas Pavlick
Corporate ControllerTeam
Cole Toohey
Research Associate IITeam
Rachel Dudum
Scientist IITeam
Payton Olson
Senior Research AssociateTeam
Kyle Austin
Laboratory AssistantTeam
Alexander Le
Senior Research AssociateTeam
Premium access

Complete people profiles for Organovo

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Organovo

4 dated milestones of Organovo across 12 years, from founding to its latest funding, stage changes and deals.

  1. Funding First funding round of $5.0M.
  2. Founded Organovo is founded.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Grant, of $1.7M.

Competitors of Organovo

Organovo has 3 listed competitors in our database, 2 of them funded. They include Dimension Inx, Prellis Biologics and FluidForm Bio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
dimensioninx.com2017Chicago, United States$15.42M
3D biomaterials are provided for regenerative medicine applications.
prellisbio.com2016San Francisco, United States$69.85M22
Provider of 3D bioprinting technology to build human tissues for drug development
fluidformbio.com2017Waltham, United States19
3D bioprinting solutions for engineered tissues are developed.
Premium access

Detailed competitors of Organovo

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Organovo

The website of Organovo (organovo.com) receives about 4K visits a month.

  • Monthly visits
    4K

    ▼ 1.7% vs previous month

Similar websites

Websites whose visitors overlap most with Organovo. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
ddw-online.com
ddw-online.com
100%
#514,775–
biospectrumindia.com
100%
#482,715View details
nature.com
97%
33.6M#1,922View details
utdr.utoledo.edu
utdr.utoledo.edu
81%
–
news.sciencemag.org
news.sciencemag.org
77%
#2,923,793–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Organovo

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in 3D Printing & Scanning Services

3 companies that operate in the same segment as Organovo (3D Printing & Scanning Services) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Platform for on-demand distributed manufacturing and prototyping is provided.
2013Gaithersburg, Maryland, United StatesUSD 200.44 MUSD 686.63 M1,090
Provider of cloud and AI-based virtual tour solutions for construction professionals
2011Sunnyvale, California, United StatesUSD 163.18 M
Hover is recognized for providing construction and renovation software solutions.
2011San Francisco, California, United StatesUSD 142.3 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Organovo

Premium access

Complete news archive for Organovo

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Organovo

Organovo was founded in 2007.

Organovo is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Organovo is a funded company, having raised a total of $6.67M across 13 funding rounds to date. The company's 1st funding round was a Grant of $142.51K, raised on Jun 2005.

Organovo has developed ExVive technology to design and create functional, three-dimensional human tissues for medical research and therapeutic applications with its proprietary scaffold-free 3D bioprinting technology. It works on the principle of interaction between drops of liquid, which come together to form multicellular aggregates, similarly mammalian cells form aggregates without the use of any component. The company calls these cellular aggregates as Bio-Ink, which would form intact tissues.It offers services in 3D Human Liver Tissue Testing, Human Liver Tissue Testing performance, and 3D Human Kidney Tissue Testing. It partners with academic institutes focusing on a single therapeutic area to develop disease modeling and therapeutics using 3D Bioprinting. The company has received orphan drug designation from the US FDA for its 3D bioprinted liver therapeutic tissue for alpha-1 antitrypsin deficiency.

Organovo's top competitors include FluidForm Bio, Prellis Biologics and Dimension Inx.

Organovo offers 3D Bioprinted Tissues and Bioprinting Technology.

Organovo has 3 investors. Key investors include NIH, HHS, and National Science Foundation.

Organovo operates through Organovo, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available